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Abstract
Introduction
Decentralization of Directly Observed Treatment (DOT) for tuberculosis (TB) to the commu-
nity (home-based DOT) has improved the coverage of TB treatment and reduced the bur-
den to the health care facilities (facility-based DOT). We aimed to compare TB treatment
outcomes in home-based and facility-based DOT under programmatic conditions in an
urban setting with a high TB burden.
Methodology
A retrospective analysis of a cohort of adult TB patients (15 years) routinely notified
between 2010 and 2013 in two representative TB sub-districts in the Temeke district, Dar
es Salaam, Tanzania. We assessed differences in treatment outcomes by calculating Risk
Ratios (RRs). We used logistic regression to assess the association between DOT and
treatment outcomes.
Results
Data of 4,835 adult TB patients were analyzed, with a median age of 35 years, 2,943
(60.9%) were men and TB/HIV co-infection prevalence of 39.9%. A total of 3,593 (74.3%)
patients were treated under home-based DOT. Patients on home-based DOT were more
likely to die compared to patients on facility-based DOT (RR 2.04, 95% Confidence Interval
[95% CI]: 1.52–2.73), and more likely to complete TB treatment (RR 1.14, 95% CI: 1.06–
1.23), but less likely to have a successful treatment outcome (RR 0.94, 95% CI: 0.92–0.97).
Home-based DOT was preferred by women (adjusted Odds Ratio [aOR] 1.55, 95% CI:
1.34–1.80, p<0.001), older people (aOR 1.01 for each year increase, 95% CI: 1.00–1.02,
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p = 0.001) and patients with extra-pulmonary TB (aOR 1.45, 95% CI: 1.16–1.81, p = 0.001),
but less frequently by patients on a retreatment regimen (aOR 0.12, 95% CI: 0.08–0.19,
p<0.001).
Conclusions/significance
TB patients under home-based DOT had more frequently risk factors of death such as older
age, HIV infection and sputum smear-negative TB, and had higher mortality compared to
patients under facility-based DOT. Further operational research is needed to monitor the
implementation of DOT under programmatic conditions.
Introduction
In 2014 globally, almost 1.5 million people died from tuberculosis (TB) from an estimated 9.6
million who developed TB [1]. TB is now the leading cause of death from an infectious disease
worldwide, surpassing those caused by Human Immunodefiency Virus [2]. Globally, TB mor-
tality trends are on the decline [1], but remain high despite effective short-course treatment
regimens [1]. In Africa, however, the decline did not meet the 2015 Stop TB Partnership goal
of a 50% decline from 1990 to 2015 [1].
Early diagnosis and effective treatment of TB are critical to reduce TB mortality and control
the spread of TB [1]. The Directly Observed Treatment Short course (DOTS) strategy recom-
mended by the World Health Organization in 1994 [3–5], has proved to be one of the most
effective public health interventions [5]. The DOTS strategy provides a comprehensive package
to control TB which consists of six components, and one of them addresses the use of standard-
ized treatment with supervision and patients supporters (directly observed therapy, DOT) [4].
DOT was pioneered in Tanzania in the 1980s, and resulted in improved cure rates from 60% to
80% [5]. TB treatment under DOT can be given at the health facility (facility-based DOT) or in
the community (home-based DOT). The facility-based DOT approach requires that patients
visit daily the health facility for supervised drug intake by health workers, with continuous
assessment of adherence to TB medication [6]. However, this delivery system places a burden
on the health care system and the patient [7,8]. This made it necessary to decentralize TB treat-
ment to the community (home-based DOT) [8,9].
Although systematic reviews showed that patients under home-based DOT can achieve sim-
ilar or better treatment outcomes compared to facility-based DOT [10,11], the implementation
of treatment under home-based DOT has also raised concerns [12]. Health care workers have
expressed concerns about treatment adherence, storage of drugs and lack of supervision under
home-based DOT which may contribute to unfavorable TB treatment outcomes [13]. We
therefore aimed to assess TB treatment outcomes in home-based and facility-based DOT
under programmatic conditions in the high TB incidence country Tanzania.
Methods
Ethics statement
We used anonymized population-level data of notified TB patients. Hence, ethical approval
and informed consent were not required for this analysis. The permission to use the data
was authorized by the Program Manager of the National TB and Leprosy Programme
(NTLP) in the Ministry of Health, Community Development, Gender, Elderly and Children
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in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
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(MoHCDGEC). All TB patients received the standardized TB treatment regimen in line with
national TB treatment guideline [6]. HIV-positive TB patients were managed in accordance to
the National Guidelines for the Management of HIV in Tanzania [14].
Study setting
Temeke is one of the three districts in Dar es Salaam region in Tanzania. Temeke is the largest
district that occupies 48.3% of the total surface area of Dar es Salaam and has a total population
of 1,368,881 [15,16]. Temeke district notified 4,373 TB patients in 2014 [17] and has HIV prev-
alence of 5.2% in the general adult population [16]. We selected Temeke district because it rep-
resents an urban setting with a high TB notification rate, and because it was one of the few
districts in Tanzania where the acceptability study of home-based and facility-based DOT was
done in 2006 [7]. The two sub-districts of Wailes I and Wailes II, as categorized by National
TB and Leprosy Programme, are densely populated areas surrounding the Temeke district hos-
pital which has the largest TB clinic serving these two sub-districts.
Study population and study definitions
We obtained anonymized electronic data from the TB district register of all adult TB patients
(aged15 years) who were notified between 2010 and 2013 in a single geographical area of
two TB sub-districts (Wailes I and Wailes II) in the Temeke district, Dar es Salaam, Tanzania.
The patient selection is presented in Fig 1. We excluded 31 patients with unknown DOT pref-
erence and 363 patients with treatment outcome “not evaluated” (“unknown” or “transferred
out”). The included and excluded (patients with unknown DOT and “not evaluated” outcome)
patients did not differ in baseline characteristics (S1 Table).
We used the study definitions according to the WHO updated guidelines [18]. A “new”
patient was defined as never had treatment for TB, or has taken anti-TB drugs for less than one
month; a “retreatment” patient was defined as previously treated patient who has received one
month or more of anti-TB drugs in the past; TB death as any death that occurred during TB
Fig 1. Selection of patients included in the study.
doi:10.1371/journal.pone.0161171.g001
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treatment. “Treatment success” combines cured and treatment completed outcomes [18].
“Unsuccessful” treatment combines failed treatment, loss to follow-up and died outcomes. Not
evaluated combines the transferred-out and unknown treatment outcomes.
Facility-based and home-based DOT
According to the national guidelines, facility-based DOT requires health care workers to super-
vise daily intake of anti-TB medication during the intensive and continuation phases [6].
While at the clinic, TB patients will also receive health education and clinical evaluation by the
clinicians and nurses. Under home-based DOT, a patient takes medication at home and is
supervised by a treatment supporter who is chosen by the TB patient [6]. The treatment sup-
porter, who can be either a family member or a neighbor, supervises anti-TB medication intake
at home on daily basis during the entire TB treatment phase [6,13]. Treatment supporters
would also accompany the TB patients to the health facility for anti-TB medication refill weekly
during the intensive phase and fortnightly during the intensive phase. TB patients with their
treatment supporters while at the health facility will receive health education from health care
workers; and TB patients will undergo a clinical evaluation [6]. Under the current Patient-Cen-
tered Treatment (PCT) approach, the patient can indicate the choice of DOT at the time of TB
diagnosis (hereafter referred as “preference of DOT”).
Laboratory investigations
TB diagnosis was made either by microbiological confirmation of acid fast bacilli (AFB) in the
sputum smear examination by Ziehl-Nielsen method or based on clinical grounds or radiologi-
cal findings as determined by the attending clinician at the TB clinic. The quality control of
smear microscopy was done by the Central Tuberculosis Reference Laboratory (CTRL) in Dar
es Salaam. AFB smear positive results was as per World Health Organization/International
Union Against Tuberculosis and Lung Disease grading: “scanty” with of 1–9 AFB per 100 oil
immersion fields; 1+” with 10–99 AFB per 100 immersion fields; “2+” with 1–10 AFB per 1
immersion field and “3+” with>10 AFB per immersion field [6,19].Tanzania also implements
collaborative TB/HIV services, and all TB patients were offered rapid HIV testing as per
National guidelines for the management of HIV and AIDS of Tanzania [14].
Statistical analyses
Descriptive statistics were used for patient characteristics, and groups were compared using
Chi-Square andWilcox rank-sum test as appropriate. We estimated treatment outcomes risk
ratios (RR) comparing patients under home-based with patients under health facility-based
DOT. We used logistic regression models to estimate the effect of home-based DOT on mortal-
ity and treatment success. The results are presented as crude and adjusted odds ratio (OR) after
adjusting for age, sex, HIV status, site of disease, AFB sputum smear results at diagnosis, and
patient category (new or retreatment patient). Point estimates are presented with their corre-
sponding 95% Confidence Intervals (95% CIs). We also performed a complete case analysis
excluding all patients with any missing value. All analyses were performed using Stata version
14.0 (Stata Corp, College Station, TX, USA).
Results
Patient characteristics
We analyzed 4,835 adult TB patients from the Temeke District, Dar es Salaam, notified
between 2010 and 2013. The median age was 35 years (Interquartile Range [IQR]: 27–44
Home-Based and Facility-Based DOT in Tuberculosis Control
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years); 2,943 (60.9%) were men. The HIV prevalence was 39.9% (95% Confidence Interval
[95% CI]: 38.5–41.3%). Home-based DOT was the most preferred (3,593 patients, 74.3%) com-
pared to facility-based DOT. Patients on home-based DOT were more likely to be HIV-posi-
tive, women, with EPTB, smear-negative at diagnosis and older (Table 1). TB/HIV co-infected
patients were more frequently men, of older age, and patients with EPTB and smear-negative
TB, and opted more often for home-based DOT (S2 Table).
TB treatment outcomes by DOT preference
Overall, treatment success which combines cured and treatment completed outcomes, was
reported in 4,006 (82.8%) patients and 345 (7.1%) patients died during TB treatment. Patients
Table 1. Baseline characteristics of TB patients at Temeke district by choice of DOT.
Characteristics All Home-based Facility-based p-value
(n = 4,835) (n = 3,593) (n = 1,242)
n (%) n (%) n (%)
Proportion of diagnosis, n (%) 4,835 (100) 3,593 (100) 1,242 (100)
Sex <0.001
Male 2,943 (60.9) 2,082 (57.9) 861 (69.3)
Female 1,892 (39.1) 1,511 (42.1) 381 (30.7)
Age in years, median (IQR) 35 (27–44) 35 (29–45) 34 (28–41) 0.007a
Age groups (years) <0.001
15–19 285 (5.9) 238 (6.6) 47 (3.8)
20–24 544 (11.3) 390 (10.9) 154 (12.4)
25–29 724 (15.0) 521 (14.5) 203 (16.3)
30–34 820 (17.0) 577 (16.1) 243 (19.6)
35–39 706 (14.6) 521 (14.5) 185 (14.9)
40–44 570 (11.8) 405 (11.3) 165 (13.3)
45–49 428 (8.9) 319 (8.9) 109 (8.8)
50–54 279 (5.8) 218 (6.1) 61 (4.9)
55 479 (9.9) 404 (11.2) 75 (6.0)
HIV status 0.002
Positive 1,927 (39.9) 1,485 (41.3) 442 (35.6)
Negative 2,582 (53.4) 1,874 (52.2) 708 (57.0)
Unknown status 326 (6.7) 234 (6.5) 92 (7.4)
Site of disease <0.001
PTB 3,977 (82.3) 2,884 (80.3) 1,093 (88.0)
EPTB 858 (17.7) 709 (19.7) 149 (12.0)
Category <0.001
New 4,706 (97.3) 3,557 (99.0) 1,149 (92.5)
Retreatment 129 (2.7) 36 (1.0) 93 (7.5)
AFB smear result at diagnosis <0.001
Smear-positive 2,438 (50.4) 1,706 (47.5) 732 (58.9)
Smear-negative 2,352 (48.6) 1,845 (51.3) 507 (40.8)
Unknown 47 (0.9) 42 (1.2) 3 (0.2)
aWilcox-ranksum test; n (%), absolute number and column percentage
Patients with unknown DOT preference were excluded (n = 31, 0.6%).
AFB, acid-fast bacilli; IQR, Interquartile Range; HIV, Human Immunodeﬁcieny Virus; TB, Tuberculosis; PTB, Pulmonary tuberculosis; EPTB,
Extrapulmonary tuberculosis; DOT, Directly Observed Treatment.
doi:10.1371/journal.pone.0161171.t001
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on home-based compared to facility-based DOT were less likely to have treatment success (RR
0.94, 95% CI: 0.92–0.97). We observed no significant difference in loss to follow-up and “not
evaluated” treatment outcomes. Treatment failure was only reported in the home-based DOT
(24 patients, 0.7%). When restricting the analysis to smear-positive TB patients, patients on
home-based DOT were less likely to be cured compared to facility-based DOT (RR, 0.93 95 CI:
0.88–0.98), and were more likely to die but the results were not significant (RR 1.35, 95% CI:
0.88–2.06). We found no statistically significant differences in all other treatment outcomes
(Table 2). Of 31 TB patients with unknown DOT preference, 2 patients died during the TB
treatment.
TBmortality and associated patient factors
TB mortality was strongly associated with home-based compared to facility-based DOT
(adjusted OR [aOR] 2.28, 95% CI: 1.64–3.18, p<0.001). Other patient factors associated with
mortality included older age (e.g45 years, aOR 2.05, 95% CI: 1.36–3.08, p<0.002), HIV-posi-
tive (aOR 1.68, 95% CI: 1.31–2.15, p<0.001), retreatment category (aOR 3.99, 95% CI: 2.33–
6.84, p<0.001) and smear-positive TB (aOR 0.49, 95% CI: 0.38–0.64, p<0.001) (Table 3). A
complete case analysis (excluding any missing values) produced similar results. S3 Table shows
the patient characteristics separately for home-based and facility-based DOT for TB patients
who were reported as dead or alive.
Successful treatment outcome and associated patient factors
Treatment success was less likely to be associated with home-based compared to facility-based
DOT (aOR 0.53, 95% CI: 0.41–0.70, p<0.001). Treatment success was less likely with increas-
ing age, among HIV-positive and patients on retreatment category and smear-negative TB
patients (Table 4).
Table 2. Differences in TB treatment outcomes among TB patients under home-based DOT compared to facility-based DOT.
Treatment outcome All Home-based DOT Facility-based DOT RR (95% CI) p-value
n (%) n (%) n (%)
All patients 4,835 3,593 (100) 1,242 (100) <0.001
Treatment success 4,006 (82.8) 2,932 (81.6) 1,073 (86.4) 0.94 (0.92–0.97)
Cured 1,738 (35.9) 1,192 (33.2) 546 (44.0) 0.75 (0.70–0.82)
Treatment completed 2,268 (46.9) 1,741 (48.5) 527 (42.4) 1.14 (1.06–1.23)
Died 345 (7.1) 295 (8.2) 50 (4.0) 2.04 (1.52–2.73)
Loss to follow-up 97 (2.0) 68 (1.9) 29 (2.3) 0.81 (0.53–1.25)
Treatment failed 24 (0.5) 24 (0.7) 0 (0) ND
Not evaluated 363 (7.5) 273 (7.6) 90 (7.2) 1.05 (0.83–1.32)
Smear-positive 2,438 (100) 1,706 (100) 732 (100) 0.024
Treatment success 2060 (84.5) 1431 (83.9) 629 (85.9) 0.98 (0.94–1.01)
Cured 1,738 (71.3) 1,192 (69.9) 546 (74.6) 0.93 (0.88–0.99)
Treatment completed 322 (13.2) 239 (14.0) 83 (11.3) 1.23 (0.98–1.56)
Died 109 (4.5) 83 (4.9) 26 (3.6) 1.35 (0.88–2.06)
Loss to follow-up 52 (2.1) 34 (2.0) 18 (2.5) 0.83 (0.48–1.46)
Treatment failed 14 (0.6) 14 (0.8) 0 (0) ND
Not evaluated 203 (8.3) 144 (8.4) 59 (8.1) 1.04(0.78–1.40)
Patients with unknown DOT preference were excluded (n = 31, 0.6%; n (%) = absolute number and column percentage
DOT, Directly Observed Treatment; RR, Risk ratio; 95% CI: 95% Conﬁdence Interval; ND, Not Deﬁned; Not evaluated; Transferred out and unknown TB
treatment outcome.
doi:10.1371/journal.pone.0161171.t002
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Patient factors associated with preference of home-based DOT
Patients opting for home-based DOT were more likely to be women (aOR 1.55, 95% CI: 1.34–
1.80, p<0.001), older (aOR 1.01, 95% CI: 1.00–1.02, p = 0.001; for each year increase in age),
more likely to have EPTB (aOR 1.45, 95% CI: 1.16–1.81, p<0.001), but less likely to have
smear-positive TB (aOR 0.80, 95% CI: 0.68–0.93, p = 0.002) and less likely to be on a retreat-
ment category (aOR 0.12, 95% CI: 0.08–0.19, p<0.001). HIV-positive TB patients tended to
prefer home-based compared to facility-based DOT (aOR 1.16, 95% CI: 0.99–1.36, p = 0.052)
(Table 5).
Discussion
We showed that TB patients who opted for home-based DOT had more frequently risk factors
for mortality and a higher mortality compared to the facility-based DOT group. The risk fac-
tors for mortality were older age (>35 years), HIV infection, smear-negative TB, and being on
a TB retreatment regimen.
Table 3. Risk factors for mortality among TB patients.
Characteristic Crude OR Adjusted OR
OR (95% CI) p-value OR (95% CI) p-value
Place of DOT <0.001 <0.001
Facility 1 (Ref) 1(Ref)
Home 2.15 (1.58–2.92) 2.28 (1.64–3.18)
Sex 0.2 0.8
Male 1 (Ref) 1 (Ref)
Female 1.14 (0.92–1.43) 0.97 (0.77–1.23)
Age groups (years) <0.001 0.002
<25 1 (Ref) 1 (Ref)
25–34 1.47 (0.97–2.22) 1.37 (0.90–2.08)
35–44 2.15 (1.44–3.22) 1.69 (1.11–2.57)
45 2.64 (1.78–3.93) 2.05 (1.36–3.08)
HIV status <0.001 <0.001
Negative 1 (Ref) 1 (Ref)
Positive 2.07 (1.65–2.61) 1.68 (1.31–2.15)
Unknown HIV status 1.11 (0.68–1.82) 0.98 (0.59–1.63)
Site of disease 0.006 0.8
PTB 1 (Ref) 1 (Ref)
EPTB 1.46 (1.12–1.89) 0.93 (0.59–1.63)
AFB smear result at diagnosis <0.001 <0.001
Smear-negative 1 (Ref) 1 (Ref)
Smear-positive 0.44 (0.35–0.56) 0.49 (0.38–0.64)
Unknown 1.82 (0.80–4.17) 1.39 (0.60–3.25)
Category of TB patient 0.001 <0.001
New 1 (Ref) 1 (Ref)
Retreatment 2.61 (1.59–4.29) 3.99 (2.33–6.84)
OR, Odds Ratio; 95% CI = 95% Conﬁdence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; HIV, Human Immunodeﬁciency Virus; TB,
Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary tuberculosis
All variables were included in the adjusted model
Excluded from the analysis: Not evaluated = Transferred-out and TB patients with unknown TB treatment outcomes, n = 363, 7.5%.
doi:10.1371/journal.pone.0161171.t003
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Our main finding demonstrated that TB mortality was strikingly higher in the home-based
compared to the facility-based DOT group under programmatic conditions. This is in contrast
to three previous studies from Tanzania [9,20,21] which showed that mortality rates were
lower or equal in the home-based compared to the facility-based DOT. A cluster randomized
trial conducted in a rural district in Tanzania done in 2003, reported mortality to be lower in
the home-based compared to facility-based DOT patient group [9]. However, the observed
results may be due to the close supervision by community-based DOT observers and health
care workers under trial conditions [9]. In 2009, shortly after the introduction of home-based
DOT in Tanzania, an observational study conducted in several urban and rural settings
reported a lower mortality in the PCT cohort (home-based DOT) compared to a historic
cohort (facility-based DOT) [21]. As the authors argue, however, the difference could be
explained by the more efficacious and shorter six-month regimen (rifampicin throughout regi-
men, a more potent anti-TB) during the PCT implementation compared to the eight months
regimen in the historic cohort. Moreover, the availability of the treatment supporters in the
PCT cohort was verified by the study team. Another observational study in the northern
Table 4. Factors associated with treatment success among adult TB patients.
Characteristic Crude OR Adjusted OR
OR (95% CI) p-value OR (95% CI) p-value
Place of DOT <0.001 <0.001
Facility-based 1 (Ref) 1 (Ref)
Home-based 0.56 (0.43–0.72) 0.53 (0.41–0.70)
Sex 0.9 0.2
Male 1 (Ref) 1 (Ref)
Female 1.0 (0.82–1.22) 1.15 (0.94–1.41)
Age groups (years) <0.001 0.03
<25 1 (Ref) 1 (Ref)
25–34 0.79 (0.57–1.09) 0.84 (0.60–1.17)
35–44 0.60 (0.43–0.83) 0.73 (0.52–1.03)
45 years 0.51 (0.37–0.70) 0.63 (0.45–0.88)
HIV status <0.001 <0.001
Negative 1 (Ref) 1 (Ref)
Positive 0.55 (0.45–0.67) 0.62 (0.50–0.77)
Unknown HIV status 0.76 (0.51–1.12) 0.81 (0.54–1.20)
Site of disease 0.046 0.7
PTB 1 (Ref) 1 (Ref)
EPTB 0.79 (0.62–0.99) 1.09 (0.84–1.41)
AFB smear results at diagnosis <0.001 <0.001
Smear-negative 1 (Ref) 1 (Ref)
Smear-positive 1.74 (1.43–2.12) 1.61 (1.29–2.01)
Unknown 0.59 (0.27–1.29) 0.74 (0.33–1.64)
Category of TB patient 0.02 <0.001
New 1 (Ref) 1 (Ref)
Retreatment 0.45 (0.28–0.72) 0.34 (0.21–0.56)
OR, Odds Ratio; 95% CI = 95% Conﬁdence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; HIV, Human Immunodeﬁciency Virus; TB,
Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary tuberculosis
All variables were included in the adjusted model
Excluded: Not evaluated = Transferred-out and TB patients with unknown TB treatment outcomes, n = 363, 7.5%.
doi:10.1371/journal.pone.0161171.t004
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Tanzania reported no difference in TB mortality in home-based compared to facility-based
DOT [20]. The higher mortality in facility-based DOT could be attributed to TB patients who
were admitted at the national TB hospital, who may have been severely sick patients referred
from other districts.
The higher mortality in the home-based DOT group could be explained by the fact that TB
patients under home-based DOT had more frequently risk factors of death such as older age
(>35 years), HIV infection and smear-negative TB. Similarly, a study from the Northern part
of Tanzania showed that HIV-positive and smear-negative TB patients preferred home-based
DOT [20]. In line with other studies from Tanzania [7,20], we found that the majority (more
than 60%) of TB patients in Tanzania appear to prefer home-based compared to facility-based
DOT. Home-based DOT could have been the likely choice because of convenience (e.g., older
people who are less mobile or severely sick TB patients) and because patient related treatment
costs are considerably lower [7,22]. Furthermore, adequate treatment supervision and adher-
ence under home-based DOT may not have been guaranteed and implemented throughout the
treatment period as stipulated in the guidelines [7,13,20], which could have caused the higher
mortality in the home-based DOT group. The overall mortality during TB treatment in our
study (7%) is comparable to previous studies in Tanzania (9%) [20], and also comparable to
Table 5. Factors associated with preference to home-based DOT.
Characteristic Crude OR Adjusted OR
OR (95% CI) p-value OR (95% CI) p-value
Sex <0.001 <0.001
Male 1 (Ref) 1 (Ref)
Female 1.63 (1.41–1.88) 1.55 (1.34–1.80)
Age groups (years) <0.001 <0.001
<25 1 (Ref) 1 (Ref)
25–34 0.78 (0.63–0.95) 0.73 (0.59–0.90)
35–44 0.83 (0.67–1.02) 0.77 (0.61–0.96)
45 years 1.24 (0.99–1.54) 1.17 (0.93–1.48)
HIV status 0.005 0.05
Negative 1 (Ref) 1 (Ref)
Positive 1.24 (1.08–1.43) 1.16 (0.99–1.36)
Unknown HIV status 0.92 (0.71–1.19) 0.86 (0.66–1.13)
Site of disease <0.001 0.001
PTB 1 (Ref) 1 (Ref)
EPTB 1.81 (1.49–2.20) 1.43 (1.14–1.78)
AFB smear results at diagnosis <0.001 0.001
Smear negative 1 (Ref) 1 (Ref)
Smear positive 0.64 (0.56–0.74) 0.78 (0.69–0.92)
Unknown smear result 3.41 (1.04–11.11) 3.38 (1.02–11.23)
Category of TB patient <0.001 <0.001
New TB patient 1 (Ref) 1 (Ref)
Retreatment 0.13 (0.08–0.19) 0.12 (0.08–0.19)
OR, Odds Ratio; 95% CI = 95% Conﬁdence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; HIV, Human Immunodeﬁciency Virus; TB,
Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary tuberculosis
EPTB, Extra-pulmonary Tuberculosis
All variables were included in the adjusted model
n = 4,472; Excluded: Not evaluated = Transferred-out and TB patients with unknown TB treatment outcomes, n = 363, 7.5%.
doi:10.1371/journal.pone.0161171.t005
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studies elsewhere in sub-Saharan Africa (5%) [23]. However, mortality was lower than in the
neighboring country Malawi (22%) [24], and lower than the global average (16%) [1].
We found that patient characteristics such as older age, HIV infection, and smear-negative
TB were risk factors for mortality. This is in line with previous reports from several countries
in sub-Saharan Africa [25–29] and a systematic review [30]. Smear-negative TB is associated
with a higher mortality possibly because smear-negative TB is more common in HIV-positive
patients with severe immunosuppression [31]. Therefore, HIV-positive patients with severe
immunosuppression may have developed the Immune Reconstitution Inflammatory Syn-
drome (IRIS), which is a consequence of the immune recovery after initiation of ART, and can
result in death [32–35]. We further speculate that other life threatening opportunistic infec-
tions such as Pneumocystis jirovecii pneumonia (PCP) [36] may have contributed to the higher
mortality in patients opting for home-based DOT. Furthermore, older age was also associated
with higher mortality, consistent with several previous studies [24,27,28,37]. Older people
often have additional comorbidities such as diabetes mellitus, hypertension and chronic
obstructive pulmonary disease (COPD) which are independently associated with increased risk
of mortality [30]. In addition, fatal hepatotoxicity due to anti-TB is more common among
older patients [38]. Finally, we also found that TB retreatment was associated with increased
mortality. Retreatment TB patients (treatment failures or treatment after loss to follow-up)
may have undetected initial or acquired drug resistance while on TB treatment [36,39], which
may contribute to a higher mortality [36]. Although the prevalence of multi-drug resistance is
low in Tanzania (3.9% among retreatment category patients, 1.1% among new TB patients)
[40], its contribution to the increased mortality cannot be ruled out.
Our study has several limitations. First, this was a retrospective analysis using routinely col-
lected data. However, we analyzed a large dataset of TB patients notified to the National TB
Programme over four years. Also the patients without the outcome of interest were equally dis-
tributed between home-based and facility-based DOT, and therefore we expect no bias of
results. Therefore, these findings may reflect the “real life” situation under the programmatic
conditions. Second, DOT preference by the patient is as recorded in the TB registers and we
could not verify if patient remained with that choice throughout the TB treatment. However,
the proportion of patients under home-based DOT in our study is very comparable to others
previous studies done in Tanzania [7,13,20]; indicating that the data used in our study reflects
the practice of DOT implementation in programmatic conditions. Third, additional factors
such as socio-economic factors, causes of death, use of cotrimoxazole prophylaxis and anti-ret-
roviral therapy (ART) and treatment supporter characteristics were not available from the rou-
tine dataset. However, we can reasonably assume that most of the TB patients included in our
study were supported by their family members [13,21,22], and the use of CPT and ART initia-
tion was given as per Tanzanian HIV and AIDS treatment guidelines [14]. Finally, we analyzed
only data from an urban setting, and thus our findings may only be generalizable to other
urban areas in sub-Saharan Africa.
In conclusion, our results demonstrated that patients opting for home-based DOT under
programmatic conditions are more likely to have risk factors for mortality and have an
increased mortality compared to facility-based DOT. Our findings suggest that there is a need
for a risk assessment of patients at the time of TB diagnosis and a need for a careful monitoring
of the implementation of DOT under programmatic conditions. The counseling and support
of TB patients during TB treatment by trained health care workers may need to be improved,
particularly in high-risk groups such as older people and those with comorbidities and co-
infections.
Future research should focus on developing simple risk assessment tools based on evidence
from prospective cohort studies [30,41] to identify patient and treatment supporter factors
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which may potentially influence mortality during TB treatment. In addition, operational
research is needed to monitor the quality of treatment supervision and performance of DOT.
Due to the limitations of current DOT strategies to assure proper drug intake [5,8], additional
new innovative public health interventions such as medication monitors and mobile text mes-
sage reminders [42] should also be considered in the transition phase to the “post-DOT” era
[43]. Combined with shortened and simplified TB treatment regimens, this may further reduce
mortality and improve clinical outcomes to ultimately meet the “End TB”WHO targets by
2035 [2].
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